(-0.06%) 5 143.75 points
(-0.02%) 38 550 points
(0.01%) 17 905 points
(-0.22%) $82.45
(1.67%) $2.06
(-1.03%) $2 333.30
(-2.10%) $27.08
(-0.52%) $956.50
(0.15%) $0.934
(0.33%) $11.02
(0.21%) $0.798
(-0.23%) $93.09
@ $2.35
发出时间: 14 Feb 2024 @ 22:33
回报率: 9.79%
上一信号: Feb 12 - 23:14
上一信号:
回报率: -12.31 %
Live Chart Being Loaded With Signals
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer...
Stats | |
---|---|
今日成交量 | 465 712 |
平均成交量 | 550 124 |
市值 | 124.11M |
EPS | $0 ( 2024-03-26 ) |
下一个收益日期 | ( $-0.570 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.000 |
ATR14 | $0.00400 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Smith Scott Andrew | Sell | 2 181 | Common Stock |
2024-03-31 | Sievers Eric | Sell | 572 | Common Stock |
2024-02-29 | Smith Scott Andrew | Sell | 2 181 | Common Stock |
2024-02-29 | Sievers Eric | Sell | 572 | Common Stock |
2024-02-15 | Waldron Richard A | Buy | 106 000 | Common Stock |
INSIDER POWER |
---|
93.82 |
Last 100 transactions |
Buy: 3 003 180 | Sell: 92 181 |
音量 相关性
BioAtla, Inc. 相关性 - 货币/商品
BioAtla, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-1.22M (0.00 %) |
EPS: | $-2.58 |
FY | 2023 |
营收: | $0 |
毛利润: | $-1.22M (0.00 %) |
EPS: | $-2.58 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.20M (0.00 %) |
EPS: | $-2.70 |
FY | 2021 |
营收: | $250 000 |
毛利润: | $250 000 (100.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。